Premium
Glucose‐6‐phosphate dehydrogenase: A possible clinical indicator for prostatic carcinoma
Author(s) -
Zampella Edward J.,
Bradley Edwin L.,
Pretlow Thomas G.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820115)49:2<384::aid-cncr2820490229>3.0.co;2-1
Subject(s) - hyperplasia , medicine , carcinoma , prostate , pathology , enzyme , endocrinology , cancer , biochemistry , biology
Any system of biochemical analysis that can be used to detect chemical differences between normal and malignant cells may add potentially valuable information to complement the histologic data which provide the practical definition of human prostatic carcinoma. A difference ( P < 0.0001) was observed in the levels of glucose‐6‐phosphate dehydrogenase (G‐6‐PD) activity in prostatic tissue with benign hyperplasia and prostatic carcinoma. Measured as a function of the amount of protein extracted from whole‐tissue homogenates, the values for G‐6‐PD activity in prostatic carcinoma are almost four times those measured for benign prostatic hyperplasia. The degree of elevation of the activity of this enzyme suggests a correlation between enzymatic activity and clinical prognosticators, ie. , histotogic differentiation and clinical stage.